Bradford Patricia A.
Wyeth-Ayerst Research, 401 Middletown Road, Pearl River, NY 10965, USA. bradfop@war,wyeth.com.
Curr Infect Dis Rep. 2001 Feb;3(1):13-19. doi: 10.1007/s11908-001-0054-z.
beta-lactamases continue to be the leading cause of resistance to beta-lactam antibiotics, among gram-negative bacteria. In recent years, both the incidence and the prevalence of extended-spectrum beta-lactamases, inhibitor-resistant beta-lactamases, AmpC-type enzymes, and both metallo- carbapenemases and nonmetallo-carbapenemases have increased. These beta-lactamases provide resistance to oximino-cephalosporins, beta-lactam/beta-lactamase inhibitor combinations, cephamycins, and carbapenems, respectively. Strains expressing these beta-lactamases will generate a host of therapeutic challenges as we begin the 21st century.
β-内酰胺酶仍然是革兰氏阴性菌对β-内酰胺类抗生素耐药的主要原因。近年来,超广谱β-内酰胺酶、耐抑制剂β-内酰胺酶、AmpC型酶、金属碳青霉烯酶和非金属碳青霉烯酶的发生率和流行率均有所上升。这些β-内酰胺酶分别使细菌对氧亚氨基头孢菌素、β-内酰胺/β-内酰胺酶抑制剂合剂、头孢霉素和碳青霉烯类产生耐药性。随着我们迈入21世纪,表达这些β-内酰胺酶的菌株将会带来一系列治疗挑战。